Surfactant has been shown to significantly increase the survival of VLBW infants. The purpose of this study was to determine the impact of increased survival on the incidence of chronic lung disease (O2 req. at 36 weeks) and developmental outcome at 7 and 18 months of age. There were 198 live births between 1990 and 1995, with 114 (57%) survivors. Data are shown by year. Table

Table 1

Survival ↑ from 46% in 1990 to 67% in 1995, (p<0.008). There was a sig. trend for ↓ b.wt (p<0.04) and ↑ O2 req. (p<0.04) between 1990 and 1995. Gest. age was neg. correlated with days O2 r=-0.37, p<.0001. Days O2 were neg. correlated with MDI, r=-0.35, p<.001, and PDI, r= -0.38, p<.0003 at 7 mo. and MDI, r= -0.27, p<.03 and PDI, r=-0.29, p<0.02 at 18 mo. We conclude that improved survival of more immature infants is associated with sig. chronic lung disease and secondary morbidities.